Cancer: SCF-mediated degradation of p100 (NF-κB2): Mechanisms and relevance in multiple myeloma

Science Signaling

Volumn 5, Issue 253, 2012, Pages

  Busino, Luca ^a   Millman, Scott E ^a   Pagano, Michele ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CULLIN; F BOX PROTEIN; GLYCOGEN SYNTHASE KINASE 3; HETERODIMER; PROTEASOME; PROTEIN P100; PROTEIN P52; SERINE; UBIQUITIN PROTEIN LIGASE; CELL CYCLE PROTEIN; FBXW7 PROTEIN, HUMAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NFKB2 PROTEIN, HUMAN; TUMOR PROTEIN;

CELL DEATH; CELL NUCLEUS; CONFERENCE PAPER; CYTOPLASM; DEPLETION; GENETIC TRANSCRIPTION; GROWTH; HUMAN; IN VITRO STUDY; INHIBITION KINETICS; MOLECULAR STABILITY; MULTIPLE MYELOMA; MUTATION; MYELOMA CELL; NONHUMAN; NUCLEAR EXPORT SIGNAL; ONCOGENE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PURIFICATION; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; UBIQUITINATION; ANIMAL; GENETICS; METABOLISM; PATHOLOGY; PROTEIN MOTIF; PROTEIN STABILITY; REVIEW;

AMINO ACID MOTIFS; ANIMALS; CELL CYCLE PROTEINS; F-BOX PROTEINS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MULTIPLE MYELOMA; NEOPLASM PROTEINS; NF-KAPPA B P52 SUBUNIT; PROTEIN STABILITY; PROTEOLYSIS; SIGNAL TRANSDUCTION; SKP CULLIN F-BOX PROTEIN LIGASES; UBIQUITIN-PROTEIN LIGASES;

EID: 84870758785     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2003408     Document Type: Conference Paper

References (28)

1. L. Busino, S. E. Millman, L. Scotto, C. A. Kyratsous, V. Basrur, O. O'Connor, A. Hoffmann, K. S. Elenitoba-Johnson, M. Pagano, Fbxw7α- and GSK3-mediated degradation of p100 is a prosurvival mechanism in multiple myeloma. Nat. Cell Biol. 14, 375-385 (2012).
2. T. Cardozo, M. Pagano, The SCF ubiquitin ligase: Insights into a molecular machine. Nat. Rev. Mol. Cell Biol. 5, 739-751 (2004).
3. M. D. Petroski, R. J. Deshaies, Function and regulation of cullin-RING ubiquitin ligases. Nat. Rev. Mol. Cell Biol. 6, 9-20 (2005).
4. J. R. Skaar, V. D'Angiolella, J. K. Pagan, M. Pagano, SnapShot: F box proteins II. Cell 137, 1358.e1-1358.e2 (2009).
5. B. J. Thompson, S. Buonamici, M. L. Sulis, T. Palomero, T. Vilimas, G. Basso, A. Ferrando, I. Aifantis, The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J. Exp. Med. 204, 1825-1835 (2007).
6. M. Welcker, B. E. Clurman, FBW7 ubiquitin ligase: A tumour suppressor at the crossroads of cell division, growth and differentiation. Nat. Rev. Cancer 8, 83-93 (2008).
7. H. Rajagopalan, P. V. Jallepalli, C. Rago, V. E. Velculescu, K. W. Kinzler, B. Vogelstein, C. Lengauer, Inactivation of hCDC4 can cause chromosomal instability. Nature 428, 77-81 (2004).
8. S. E. Millman, M. Pagano, MCL1 meets its end during mitotic arrest. EMBO Rep. 12, 384-385 (2011).
9. B. Hao, S. Oehlmann, M. E. Sowa, J. W. Harper, N. P. Pavletich, Structure of a Fbw7-Skp1-cyclin E complex: Multisite-phosphorylated substrate recognition by SCF ubiquitin ligases. Mol. Cell 26, 131-143 (2007).
10. S. Ghosh, M. Karin, Missing pieces in the NF-kappaB puzzle. Cell 109 (suppl.), S81-S96 (2002).
11. U. Senftleben, Y. Cao, G. Xiao, F. R. Greten, G. Krähn, G. Bonizzi, Y. Chen, Y. Hu, A. Fong, S. C. Sun, M. Karin, Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science 293, 1495-1499 (2001).
12. E. Dejardin, N. M. Droin, M. Delhase, E. Haas, Y. Cao, C. Makris, Z. W. Li, M. Karin, C. F. Ware, D. R. Green, The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity 17, 525-535 (2002).
13. H. J. Coope, P. G. Atkinson, B. Huhse, M. Belich, J. Janzen, M. J. Holman, G. G. Klaus, L. H. Johnston, S. C. Ley, CD40 regulates the processing of NF-kappaB2 p100 to p52. EMBO J. 21, 5375-5385 (2002).
14. F. Weih, J. Caamaño, Regulation of secondary lymphoid organ development by the nuclear factor-kappaB signal transduction pathway. Immunol. Rev. 195, 91-105 (2003).
15. P. Ramakrishnan, W. Wang, D. Wallach, Receptor-specific signaling for both the alternative and the canonical NF-kappaB activation pathways by NF-kappaB-inducing kinase. Immunity 21, 477-489 (2004).
16. B. Zarnegar, J. Q. He, G. Oganesyan, A. Hoffmann, D. Baltimore, G. Cheng, Unique CD40- mediated biological program in B cell activation requires both type 1 and type 2 NF-kappaB activation pathways. Proc. Natl. Acad. Sci. U.S.A. 101, 8108-8113 (2004).
17. S. Basak, H. Kim, J. D. Kearns, V. Tergaonkar, E. O'Dea, S. L. Werner, C. A. Benedict, C. F. Ware, G. Ghosh, I. M. Verma, A. Hoffmann, A fourth IkappaB protein within the NF-kappaB signaling module. Cell 128, 369-381 (2007).
18. B. Mordmüller, D. Krappmann, M. Esen, E. Wegener, C. Scheidereit, Lymphotoxin and lipopolysaccharide induce NF-kappaB-p52 generation by a co-translational mechanism. EMBO Rep. 4, 82-87 (2003).
19. G. Xiao, E. W. Harhaj, S. C. Sun, NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100. Mol. Cell 7, 401-409 (2001).
20. A. Fong, S. C. Sun, Genetic evidence for the essential role of beta-transducin repeat-containing protein in the inducible processing of NF-kappa B2/p100. J. Biol. Chem. 277, 22111-22114 (2002).
21. J. O'Neil, J. Grim, P. Strack, S. Rao, D. Tibbitts, C. Winter, J. Hardwick, M. Welcker, J. P. Meijerink, R. Pieters, G. Draetta, R. Sears, B. E. Clurman, A. T. Look, FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J. Exp. Med. 204, 1813-1824 (2007).
22. N. Stransky, A. M. Egloff, A. D. Tward, A. D. Kostic, K. Cibulskis, A. Sivachenko, G. V. Kryukov, M. S. Lawrence, C. Sougnez, A. McKenna, E. Shefler, A. H. Ramos, P. Stojanov, S. L. Carter, D. Voet, M. L. Cortés, D. Auclair, M. F. Berger, G. Saksena, C. Guiducci, R. C. Onofrio, M. Parkin, M. Romkes, J. L. Weissfeld, R. R. Seethala, L. Wang, C. Rangel-Escareño, J. C. Fernandez-Lopez, A. Hidalgo-Miranda, J. Melendez-Zajgla, W. Winckler, K. Ardlie, S. B. Gabriel, M. Meyerson, E. S. Lander, G. Getz, T. R. Golub, L. A. Garraway, J. R. Grandis, The mutational landscape of head and neck squamous cell carcinoma. Science 333, 1157-1160 (2011); 10.1126/science.1208130.
23. M. A. Chapman, M. S. Lawrence, J. J. Keats, K. Cibulskis, C. Sougnez, A. C. Schinzel, C. L. Harview, J. P. Brunet, G. J. Ahmann, M. Adli, K. C. Anderson, K. G. Ardlie, D. Auclair, A. Baker, P. L. Bergsagel, B. E. Bernstein, Y. Drier, R. Fonseca, S. B. Gabriel, C. C. Hofmeister, S. Jagannath, A. J. Jakubowiak, A. Krishnan, J. Levy, T. Liefeld, S. Lonial, S. Mahan, B. Mfuko, S. Monti, L. M. Perkins, R. Onofrio, T. J. Pugh, S. V. Rajkumar, A. H. Ramos, D. S. Siegel, A. Sivachenko, A. K. Stewart, S. Trudel, R. Vij, D. Voet, W. Winckler, T. Zimmerman, J. Carpten, J. Trent, W. C. Hahn, L. A. Garraway, M. Meyerson, E. S. Lander, G. Getz, T. R. Golub, Initial genome sequencing and analysis of multiple myeloma. Nature 471, 467-472 (2011).
24. S. Akhoondi, D. Sun, N. von der Lehr, S. Apostolidou, K. Klotz, A. Maljukova, D. Cepeda, H. Fiegl, D. Dafou, C. Marth, E. Mueller-Holzner, M. Corcoran, M. Dagnell, S. Z. Nejad, B. N. Nayer, M. R. Zali, J. Hansson, S. Egyhazi, F. Petersson, P. Sangfelt, H. Nordgren, D. Grander, S. I. Reed, M. Widschwendter, O. Sangfelt, C. Spruck, FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res. 67, 9006-9012 (2007).
25. R. D. Morin, M. Mendez-Lago, A. J. Mungall, R. Goya, K. L. Mungall, R. D. Corbett, N. A. Johnson, T. M. Severson, R. Chiu, M. Field, S. Jackman, M. Krzywinski, D. W. Scott, D. L. Trinh, J. Tamura-Wells, S. Li, M. R. Firme, S. Rogic, M. Griffith, S. Chan, O. Yakovenko, I. M. Meyer, E. Y. Zhao, D. Smailus, M. Moksa, S. Chittaranjan, L. Rimsza, A. Brooks-Wilson, J. J. Spinelli, S. Ben-Neriah, B. Meissner, B. Woolcock, M. Boyle, H. McDonald, A. Tam, Y. Zhao, A. Delaney, T. Zeng, K. Tse, Y. Butterfield, I. Birol, R. Holt, J. Schein, D. E. Horsman, R. Moore, S. J. Jones, J. M. Connors, M. Hirst, R. D. Gascoyne, M. A. Marra, Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476, 298-303 (2011).
26. L. M. Staudt, Oncogenic activation of NF-kappaB. Cold Spring Harb. Perspect. Biol. 2, a000109 (2010).
27. C. M. Annunziata, R. E. Davis, Y. Demchenko, W. Bellamy, A. Gabrea, F. Zhan, G. Lenz, I. Hanamura, G. Wright, W. Xiao, S. Dave, E. M. Hurt, B. Tan, H. Zhao, O. Stephens, M. Santra, D. R. Williams, L. Dang, B. Barlogie, J. D. Shaughnessy Jr., W. M. Kuehl, L. M. Staudt, Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12, 115-130 (2007).
28. J. J. Keats, R. Fonseca, M. Chesi, R. Schop, A. Baker, W. J. Chng, S. Van Wier, R. Tiedemann, C. X. Shi, M. Sebag, E. Braggio, T. Henry, Y. X. Zhu, H. Fogle, T. Price-Troska, G. Ahmann, C. Mancini, L. A. Brents, S. Kumar, P. Greipp, A. Dispenzieri, B. Bryant, G. Mulligan, L. Bruhn, M. Barrett, R. Valdez, J. Trent, A. K. Stewart, J. Carpten, P. L. Bergsagel, Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 12, 131-144 (2007).